Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Phase III

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
A Global, Multi-center, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Efficacy, Safety, and Immunogenicity of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) in Adults Aged 18 Years and Older
Epistemonikos ID: 4ffc30ca7ff4d4b50307fa4f952fb659c53b4e4a
First added on: Oct 28, 2021